https://viralgen.com/resources/streamlining-advanced-therapy-medicinal-product-manufacturing-a-platform-approach-for-accelerating-gene-therapy-commercializationhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Screenshot%202024-09-24%20at%2010.28.29%20AM%201.pngScreenshot 2024-09-24 at 10.28.29 AM 1Screenshot 2024-09-24 at 10.28.29 AM 1https://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2025-10-03https://viralgen.com/news/susana-solis-perez-member-of-european-parliament-visited-viralgenhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/resources/navigating-variability-and-scalability-challenges-in-aav-production2025-03-14https://viralgen.com/insights/inversiones-para-la-creacion-de-un-nuevo-laboratorio-de-control-de-calidad-askbio-center-of-excellence-ace2024-09-27https://viralgen.com/resources/addressing-the-complex-regulatory-environment-for-gene-therapieshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-01-17https://viralgen.com/news/viralgen-partners-vallabh-minikel-deverman-lab-broad-institute-gene-therapy-prion-disease2025-01-21https://viralgen.com/resources/digital-standardization-accelerating-gene-therapy-tech-transfer-with-confidence-and-compliancehttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/LSC%20Whitepaper_scientist.pngLSC Whitepaper_scientistLSC Whitepaper_scientisthttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2026-05-11https://viralgen.com/process/aavahttps://viralgen.com/hubfs/VRLG-26-007-03%20-%2001%20Foundations_Aava_1080p.mp4/medium.jpgVRLG-26-007-03 - 01 Foundations_Aava_1080pVRLG-26-007-03 - 01 Foundations_Aava_1080phttps://viralgen.com/hubfs/VRLG-26-007-03%20-%2001%20Foundations_Aava_1080p.mp4135nonohttps://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4/medium.jpgLife Science In Action VIRALGEN 11_12 v3Life Science In Action VIRALGEN 11_12 v3https://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4120nonohttps://viralgen.com/hubfs/Aava-section-shape-gen26.pngAava-section-shape-gen26Aava-section-shape-gen26https://viralgen.com/hubfs/icon_predict%201-1.pngicon_predict 1-1icon_predict 1-1https://viralgen.com/hubfs/AAVA%20Iturri_1%201.pngAAVA Iturri_1 1AAVA Iturri_1 1https://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Imagehttps://viralgen.com/hubfs/60%2B.svg60+60+https://viralgen.com/hubfs/vrlg-green-play-arrow-2.svgvrlg-green-play-arrow-2vrlg-green-play-arrow-2https://viralgen.com/hubfs/Aava-section-gem-shape.pngAava-section-gem-shapeAava-section-gem-shapehttps://viralgen.com/hubfs/VRLG-Aava-website-art.svgVRLG-Aava-website-artVRLG-Aava-website-arthttps://viralgen.com/hubfs/Group%20108.pngGroup 108Group 108https://viralgen.com/hubfs/Triple-Plasmid%20Transfection-1.pngTriple-Plasmid Transfection-1Triple-Plasmid Transfection-1https://viralgen.com/hubfs/VRLG%20ASGCT%202026_post%20event%20blog_1200x627_v1.gifVRLG ASGCT 2026_post event blog_1200x627_v1VRLG ASGCT 2026_post event blog_1200x627_v1https://viralgen.com/hubfs/100%25.svg100%100%https://viralgen.com/hubfs/Aava-section-shape-3.pngAava-section-shape-3Aava-section-shape-3https://viralgen.com/hubfs/AAVA-cta-section-background.pngAAVA-cta-section-backgroundAAVA-cta-section-backgroundhttps://viralgen.com/hubfs/icon_deep%20data%201-2.pngicon_deep data 1-2icon_deep data 1-2https://viralgen.com/hubfs/Aava-section-shape.pngAava-section-shapeAava-section-shapehttps://viralgen.com/hubfs/100%25%206.svg100% 6100% 6https://viralgen.com/hubfs/AAV%20Mendi_1-1.pngAAV Mendi_1-1AAV Mendi_1-1https://viralgen.com/hubfs/icon_fast%201-1.pngicon_fast 1-1icon_fast 1-1https://viralgen.com/hubfs/100%25%205.svg100% 5100% 5https://viralgen.com/hubfs/41.svg4141https://viralgen.com/hubfs/Aava_no%20tm%201.svgAava_no tm 1Aava_no tm 1https://viralgen.com/hubfs/Viralgen%20Science%20In%20Action%20blog_opt1_V1.gifViralgen Science In Action blog_opt1_V1Viralgen Science In Action blog_opt1_V12026-05-12https://viralgen.com/news/the-basque-national-orchestra-debutes-in-poland-with-a-tour-of-four-concerts2024-11-22https://viralgen.com/resources/displacement-chromatography-for-enrichment-of-raav-genome-containing-capsids-using-weak-organic-acidhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2024-11-22https://viralgen.com/insights/digital-transformation-at-viralgenhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2025-07-31https://viralgen.com/insights/harnessing-ai-for-faster-and-more-efficient-development-manufacturing-of-life-changing-gene-therapieshttps://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4/medium.jpgLife Science In Action VIRALGEN 11_12 v3Life Science In Action VIRALGEN 11_12 v3https://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4120nonohttps://viralgen.com/hubfs/VRLG%20ASGCT%202026_post%20event%20blog_1200x627_v1.gifVRLG ASGCT 2026_post event blog_1200x627_v1VRLG ASGCT 2026_post event blog_1200x627_v1https://viralgen.com/hubfs/Viralgen%20Science%20In%20Action%20blog_opt1_V1.gifViralgen Science In Action blog_opt1_V1Viralgen Science In Action blog_opt1_V1https://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Image2025-07-28https://viralgen.com/insights/viralgen-vector-core-s-l-leading-a-joint-effort-in-revolutionary-gene-therapy-advancementshttps://viralgen.com/hubfs/Gob%20Vasco.pngGob VascoGob Vascohttps://viralgen.com/hubfs/Cofinanciado%20por%20la%20UE.pngCofinanciado por la UECofinanciado por la UE2026-04-30https://viralgen.com/news/viralgen-elaaj-bio-to-advance-gene-therapyhttps://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/VRLG%20Apertura%20Press%20Release_1200x627_v1.1.gifVRLG Apertura Press Release_1200x627_v1.1VRLG Apertura Press Release_1200x627_v1.12026-05-05https://viralgen.com/insights/supporting-innovation-through-aav-manufacturing-a-visit-from-donostia-mayorhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/VRLG%20blog_2026_Visit%20from%20Donostia%20Mayor_v1.gifVRLG blog_2026_Visit from Donostia Mayor_v1VRLG blog_2026_Visit from Donostia Mayor_v1https://viralgen.com/hubfs/VRGL_Donostia_visit.jpgVRGL_Donostia_visitVRGL_Donostia_visit2026-07-16https://viralgen.com/sustainability-policy2025-07-31https://viralgen.com/news/viralgen-inaugurates-its-new-msat-laboratory-in-donostia2024-09-26https://viralgen.com/news/askbio-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meetinghttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/VRLG%20Apertura%20Press%20Release_1200x627_v1.1.gifVRLG Apertura Press Release_1200x627_v1.1VRLG Apertura Press Release_1200x627_v1.1https://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease2026-05-07https://viralgen.com/who-we-arehttps://viralgen.com/hubfs/Brand%20Assets/Videos/VIRALGEN-ESGCT-LOOP-4K.mp4/medium.jpgViralgen: ALL-IN AAVVIRALGEN-ESGCT-LOOP-4Khttps://viralgen.com/hubfs/Brand%20Assets/Videos/VIRALGEN-ESGCT-LOOP-4K.mp4106nonohttps://viralgen.com/hubfs/Geo%20meeting_1-1.pngGeo meeting_1-1Geo meeting_1-1https://viralgen.com/hubfs/Viralgen_Mark-Ellison.pngViralgen_Mark-EllisonViralgen_Mark-Ellisonhttps://viralgen.com/hubfs/Who-we-are-section-shape-2-1.pngWho-we-are-section-shape-2-1Who-we-are-section-shape-2-1https://viralgen.com/hubfs/Who-we-are-gem-shape-1-1.pngWho-we-are-gem-shape-1-1Who-we-are-gem-shape-1-1https://viralgen.com/hubfs/Who-we-are-section-shape-gen26.pngWho-we-are-section-shape-gen26Who-we-are-section-shape-gen26https://viralgen.com/hubfs/Who-we-are-section-shape-2.pngWho-we-are-section-shape-2Who-we-are-section-shape-22026-05-12https://viralgen.com/resources/breaking-through-the-challenges-of-raav-purity-characterization-by-ce-sds2024-11-18https://viralgen.com/information-security-policy2025-07-31https://viralgen.com/eventshttps://viralgen.com/hubfs/ESGCT%202026%20Featured%20Image%20v1.4.gifESGCT 2026 Featured Image v1.4ESGCT 2026 Featured Image v1.4https://viralgen.com/hubfs/Sociedad%20Espa%C3%B1ola%20de%20Terapia%20G%C3%A9nica%20y%20Celular%202026%20Featured%20Image%20v1.2.gifSociedad Española de Terapia Génica y Celular 2026 Featured Image v1.2Sociedad Española de Terapia Génica y Celular 2026 Featured Image v1.2https://viralgen.com/hubfs/Rare%20Drug%20Development%20Symposium%202026%20Featured%20Image%20v1.4.gifRare Drug Development Symposium 2026 Featured Image v1.4Rare Drug Development Symposium 2026 Featured Image v1.4https://viralgen.com/hubfs/BIOSpain%202026%20Featured%20Image%20v1.3.gifBIOSpain 2026 Featured Image v1.3BIOSpain 2026 Featured Image v1.3https://viralgen.com/hubfs/Advanced%20Therpaies%20USA%20Featured%20Image%20v1.2.gifAdvanced Therpaies USA Featured Image v1.2Advanced Therpaies USA Featured Image v1.2https://viralgen.com/hubfs/Viralgen%202026%20events_MotM_V1.gifViralgen 2026 events_MotM_V1Viralgen 2026 events_MotM_V12026-07-20https://viralgen.com/what-we-dohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Other-manufacturers-X.svgOther-manufacturers-XOther-manufacturers-Xhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Group%20114.pngGroup 114Group 114https://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/Geo%20texture%20light%202%201.pngGeo texture light 2 1Geo texture light 2 12026-05-13https://viralgen.com/news/visit-of-lehendakari-imanol-pradales-and-his-team-to-viralgen-facilitieshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/es/insights/la-ia-como-catalizador-para-transformar-vidas-permitiendo-un-desarrollo-y-fabricacion-de-terapias-genicas-mas-veloz-y-eficaz2025-07-28https://viralgen.com/insights/rare-disease-day-2026https://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/PXL_20260227_114129669.jpegPXL_20260227_114129669PXL_20260227_114129669https://viralgen.com/hubfs/PXL_20260227_084423778.PORTRAIT.jpegPXL_20260227_084423778.PORTRAITPXL_20260227_084423778.PORTRAIThttps://viralgen.com/hubfs/PXL_20260227_140911669.PORTRAIT.jpegPXL_20260227_140911669.PORTRAITPXL_20260227_140911669.PORTRAIThttps://viralgen.com/hubfs/PXL_20260227_100401277.jpegPXL_20260227_100401277PXL_20260227_100401277https://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Imagehttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2026-03-30https://viralgen.com/resources/facing-the-dual-scientific-and-financial-challenges-to-advance-cell-and-gene-therapieshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-03-14https://viralgen.com/resources/the-problem-of-partials-redefining-the-analytical-frameworks-surrounding-capsid-characterizationhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/VRLG-LSC%20Article_Resource_V1_LSC%20Article_Vial.jpgVRLG-LSC Article_Resource_V1_LSC Article_VialVRLG-LSC Article_Resource_V1_LSC Article_Vialhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2026-05-11https://viralgen.com/resources/webinar-every-day-countshttps://viralgen.com/hubfs/Life%20Science%20Connect%20Webinar.mp4/medium.jpgLife Science Connect WebinarLife Science Connect Webinarhttps://viralgen.com/hubfs/Life%20Science%20Connect%20Webinar.mp42062nonohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Viralgen%20Webinar%20Ane%20Quesada%20PhD.gifViralgen Webinar Ane Quesada PhDViralgen Webinar Ane Quesada PhD2025-12-12https://viralgen.com/resources/leveraging-platform-and-process-characterization-data-to-accelerate-cgt-validation-and-commercializationhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-01-17https://viralgen.com/resources/white-paper-a-proprietary-mammalian-suspension-technology-for-scalable-raav-production-the-pro10-cell-linehttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-03-14https://viralgen.com/resources/repeatability-and-intermediate-precision-of-a-genome-integrity-assay-for-raav-by-long-read-sequencinghttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Multivariate%20Approach%20to%20small-scale%20Model%20Qualification%20(SSMQ)%20in%20Upstream%20(USP)%20Adeno-Associated%20Virus%20(AAV)%20Production-1.pngMultivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1Multivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1https://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2026-06-01https://viralgen.com/offline2026-05-27https://viralgen.com/insights/successful-meeting-at-the-asgct-2023https://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/news/viralgen-welcomes-the-visit-of-alberto-nunez-feijoo-president-of-spain-s-partido-popular2024-09-26https://viralgen.com/resources/comparing-ultracentrifugation-versus-aex-for-successful-aav-purification2025-03-14https://viralgen.com/insights/reflections-on-inclusion-and-diversity-with-sonia-guirado-from-eurofirms-foundationhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/resources/industry-takeaways-from-fdas-cell-and-gene-therapy-listening-sessionhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/10760_20251020115848541_gen_17thoct_1400et_od.mp4/medium.jpg10760_20251020115848541_gen_17thoct_1400et_od10760_20251020115848541_gen_17thoct_1400et_odhttps://viralgen.com/hubfs/10760_20251020115848541_gen_17thoct_1400et_od.mp43256nonohttps://viralgen.com/hubfs/GEN%20Webinar%20Panelists.svgGEN Webinar PanelistsGEN Webinar Panelistshttps://viralgen.com/hubfs/VRLG%20GEN%20Webinar%20Oct%202025%20Feature%20Image%20(1).pngVRLG GEN Webinar Oct 2025 Feature Image (1)VRLG GEN Webinar Oct 2025 Feature Image (1)https://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2025-10-24https://viralgen.com/insights/viralgen-asgct-what-we-saw-what-to-keep-an-eye-onhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/20260514_154037.jpg20260514_15403720260514_154037https://viralgen.com/hubfs/20260513_123754.jpg20260513_12375420260513_123754https://viralgen.com/hubfs/VRLG%20ASGCT%202026_post%20event%20blog_1200x627_v1.gifVRLG ASGCT 2026_post event blog_1200x627_v1VRLG ASGCT 2026_post event blog_1200x627_v1https://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2026-06-01https://viralgen.com/resources/taav-and-viralgen-together-as-your-raav-manufacturing-solution2024-10-22https://viralgen.com/es/insights2025-01-31https://viralgen.com/es/insights/transformaci%C3%B3n-digital-en-viralgenhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-01-31https://viralgen.com/resources/enhancing-aav6-vector-production-for-cell-therapies2024-10-16https://viralgen.com/news/viralgen-collaborates-with-trogenix-to-advance-aav-gene-therapy-for-gliobastomahttps://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V12025-05-06https://viralgen.com/process-developmenthttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2026-05-19https://viralgen.com/news/askbio-announces-6-presentations-at-the-european-society-of-gene-and-cell-therapy-32nd-annual-meetinghttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/ESGCT%20AskBio%20PR%20Featured%20Image.pngESGCT AskBio PR Featured ImageESGCT AskBio PR Featured Imagehttps://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease2025-10-02https://viralgen.com/insightshttps://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4/medium.jpgLife Science In Action VIRALGEN 11_12 v3Life Science In Action VIRALGEN 11_12 v3https://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4120nonohttps://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Imagehttps://viralgen.com/hubfs/VRLG%20ASGCT%202026_post%20event%20blog_1200x627_v1.gifVRLG ASGCT 2026_post event blog_1200x627_v1VRLG ASGCT 2026_post event blog_1200x627_v1https://viralgen.com/hubfs/Viralgen%20Science%20In%20Action%20blog_opt1_V1.gifViralgen Science In Action blog_opt1_V1Viralgen Science In Action blog_opt1_V1https://viralgen.com/hubfs/VRLG_2025%20Conference%20Recap_v1.gifVRLG_2025 Conference Recap_v1VRLG_2025 Conference Recap_v1https://viralgen.com/hubfs/VRLG%20blog_2026_Visit%20from%20Donostia%20Mayor_v1.gifVRLG blog_2026_Visit from Donostia Mayor_v1VRLG blog_2026_Visit from Donostia Mayor_v12025-01-24https://viralgen.com/insights/viralgen-vector-core-and-elpida-therapeutics-partner-to-manufacture-gene-therapy-medicines-for-anticipated-spastic-paraplegia-50-spg50-and-charcot-marie-tooth-diseasehttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/news/viralgen-joins-orphan-therapeutics-accelerator-clinical-development-network-as-a-manufacturing-partner-to-advance-rare-disease-therapieshttps://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V12025-05-14https://viralgen.com/resources/outsourced-pharma-capacity-update-july-2025https://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen%20@%20OPCU%20-%20July%2017th%202025.mp4/medium.jpgViralgen Outsourced Pharma Capacity Update July 2025 - Fill/FinishDon't miss Viralgen's presentation at Outsourced Pharma's Cell & Gene Therapy Capacity Update, where CCO Andy Holt unveiled an exciting initiative that will accelerate data acquisition for investor funding. Watch now us to discover how Viralgen drives industry progress through innovation and strategic support.https://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen%20@%20OPCU%20-%20July%2017th%202025.mp41235nonohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-09-24https://viralgen.com/resources/exploring-key-regulatory-considerations-to-ensure-patient-safety-in-the-gene-therapy-spacehttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-07-09https://viralgen.com/insights/rare-disease-day-2025https://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2026-01-23https://viralgen.com/cookies-policy2026-07-06https://viralgen.com/insights/science-in-actionhttps://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4/medium.jpgLife Science In Action VIRALGEN 11_12 v3Life Science In Action VIRALGEN 11_12 v3https://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4120nonohttps://viralgen.com/hubfs/Viralgen%20Science%20In%20Action%20blog_opt1_V1.gifViralgen Science In Action blog_opt1_V1Viralgen Science In Action blog_opt1_V1https://viralgen.com/hubfs/VRLG%20ASGCT%202026_post%20event%20blog_1200x627_v1.gifVRLG ASGCT 2026_post event blog_1200x627_v1VRLG ASGCT 2026_post event blog_1200x627_v1https://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Image2026-01-28https://viralgen.com/insights/inversiones-para-la-creacion-de-un-nuevo-servicio-de-caracterizacion-de-proceso-de-fabricacion-industrial-de-vectores-virales-aav-msathttps://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Image2024-09-26https://viralgen.com/resources/nedna-is-a-robust-alternative-to-plasmid-dna-for-aav-production2024-10-16https://viralgen.com/news/viralgen-and-axovia-partner-to-manufacture-an-investigational-gene-therapy-for-retinal-dystrophy-in-bardet-biedl-syndrome-bbs-patientshttps://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v12025-01-22https://viralgen.com/resources/overcoming-variability-and-scaling-challenges-in-aav-manufacturing2025-03-14https://viralgen.com/privacy-policy2025-07-31https://viralgen.com/resources/ddpcr-based-quantification-and-fragment-analysis-of-residual-e1a-in-raav-products-method-validation-and-correlation-with-total-host-cell-dnahttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Multivariate%20Approach%20to%20small-scale%20Model%20Qualification%20(SSMQ)%20in%20Upstream%20(USP)%20Adeno-Associated%20Virus%20(AAV)%20Production-1.pngMultivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1Multivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1https://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2026-06-01https://viralgen.com/insights/visit-us-at-phacilitate-advanced-therapies-week-in-miamihttps://viralgen.com/hubfs/VRLG_2025%20Conference%20Recap_v1.gifVRLG_2025 Conference Recap_v1VRLG_2025 Conference Recap_v12024-09-27https://viralgen.com/news/javier-garcia-receives-the-tambor-de-oro-20232024-09-30https://viralgen.com/resourceshttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Screenshot%202024-09-24%20at%2010.28.29%20AM%201.pngScreenshot 2024-09-24 at 10.28.29 AM 1Screenshot 2024-09-24 at 10.28.29 AM 1https://viralgen.com/hubfs/VRLG%20GEN%20Webinar%20Oct%202025%20Feature%20Image%20(1).pngVRLG GEN Webinar Oct 2025 Feature Image (1)VRLG GEN Webinar Oct 2025 Feature Image (1)https://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Multivariate%20Approach%20to%20small-scale%20Model%20Qualification%20(SSMQ)%20in%20Upstream%20(USP)%20Adeno-Associated%20Virus%20(AAV)%20Production-1.pngMultivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1Multivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1https://viralgen.com/hubfs/VRLG-LSC%20Article_Resource_V1_LSC%20Article_Vial.jpgVRLG-LSC Article_Resource_V1_LSC Article_VialVRLG-LSC Article_Resource_V1_LSC Article_Vialhttps://viralgen.com/hubfs/LSC%20Whitepaper_scientist.pngLSC Whitepaper_scientistLSC Whitepaper_scientisthttps://viralgen.com/hubfs/Viralgen%20Webinar%20Ane%20Quesada%20PhD.gifViralgen Webinar Ane Quesada PhDViralgen Webinar Ane Quesada PhDhttps://viralgen.com/hubfs/VRLG_MotM%202025%20Webinar_1200x627_v1.gifVRLG_MotM 2025 Webinar_1200x627_v1VRLG_MotM 2025 Webinar_1200x627_v1https://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencing2025-01-24https://viralgen.com/resources/enhancing-cmc-regulatory-efficiency-in-gene-therapy2024-10-21https://viralgen.com/insights/advanced-therapies-conference-recap-key-takeaways-from-key-cgt-fall-conferences2025-11-11https://viralgen.com/facilitieshttps://viralgen.com/hubfs/06%20-%20Utility%20_%20Power%20Systems%20Final.mp4/medium.jpgViralgen Utility & Power Systems06 - Utility _ Power Systems Finalhttps://viralgen.com/hubfs/06%20-%20Utility%20_%20Power%20Systems%20Final.mp430nonohttps://viralgen.com/hubfs/04%20-%20Fill%20&%20Finish%20Final.mp4/medium.jpgViralgen Fill & Finish04 - Fill & Finish Finalhttps://viralgen.com/hubfs/04%20-%20Fill%20&%20Finish%20Final.mp430nonohttps://viralgen.com/hubfs/03%20-%20Downstream%20Final.mp4/medium.jpgViralgen Downstream Suites03 - Downstream Finalhttps://viralgen.com/hubfs/03%20-%20Downstream%20Final.mp430nonohttps://viralgen.com/hubfs/01%20-%20Cell%20Expansion%20Final.mp4/medium.jpgViralgen Cell Expansion Suites01 - Cell Expansion Finalhttps://viralgen.com/hubfs/01%20-%20Cell%20Expansion%20Final.mp430nonohttps://viralgen.com/hubfs/07%20-%20Quality%20Control%20Final.mp4/medium.jpgViralgen Quality Control Labs07 - Quality Control Finalhttps://viralgen.com/hubfs/07%20-%20Quality%20Control%20Final.mp430nonohttps://viralgen.com/hubfs/08%20-%20MSAT%20Final.mp4/medium.jpgViralgen Manufacturing, Science and Technology Laboratory08 - MSAT Finalhttps://viralgen.com/hubfs/08%20-%20MSAT%20Final.mp430nonohttps://viralgen.com/hubfs/05%20-%20Product%20Handling%20_%20Support%20Spaces%20Final.mp4/medium.jpgViralgen Product Handling & Support Space05 - Product Handling _ Support Spaces Finalhttps://viralgen.com/hubfs/05%20-%20Product%20Handling%20_%20Support%20Spaces%20Final.mp430nonohttps://viralgen.com/hubfs/02%20-%20Upstream%20Final.mp4/medium.jpgViralgen Upstream Suites02 - Upstream Finalhttps://viralgen.com/hubfs/02%20-%20Upstream%20Final.mp430nonohttps://viralgen.com/hubfs/Facilities-gen26-hero-background.pngFacilities-gen26-hero-backgroundFacilities-gen26-hero-backgroundhttps://viralgen.com/hubfs/Facilities-gem-shape-1.pngFacilities-gem-shape-1Facilities-gem-shape-1https://viralgen.com/hubfs/Facilities-section-shape-1.pngFacilities-section-shape-1Facilities-section-shape-1https://viralgen.com/hubfs/Group%2091%20(1).pngGroup 91 (1)Group 91 (1)https://viralgen.com/hubfs/Facilities-grid-accent-gen26.pngFacilities-grid-accent-gen26Facilities-grid-accent-gen26https://viralgen.com/hubfs/Facilities-image-mask-1-gen26.pngFacilities-image-mask-1-gen26Facilities-image-mask-1-gen26https://viralgen.com/hubfs/home_1001-small%202%20(1).pnghome_1001-small 2 (1)home_1001-small 2 (1)2026-05-19https://viralgen.com/news/we-are-moving-towards-a-more-sustainable-future-with-solar-energyhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2024-11-22https://viralgen.com/resources/working-with-regulators-to-get-gene-therapies-to-more-patients2024-10-16https://viralgen.com/early-phase-productionhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2026-05-19https://viralgen.com/insights/viralgen-at-the-asgct-26th-annual-meetinghttps://viralgen.com/hubfs/VRLG_2025%20Conference%20Recap_v1.gifVRLG_2025 Conference Recap_v1VRLG_2025 Conference Recap_v12024-09-30https://viralgen.com/resources/leveraging-historical-data-and-percentile-based-modeling-for-improved-aav-production-scalinghttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-07-23https://viralgen.com/news/apertura-gene-therapy-and-viralgen-announce-strategic-collaborationhttps://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/VRLG%20Apertura%20Press%20Release_1200x627_v1.1.gifVRLG Apertura Press Release_1200x627_v1.1VRLG Apertura Press Release_1200x627_v1.12026-03-17https://viralgen.com/resources/multivariate-approach-to-ssmq-in-upstream-aav-productionhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Multivariate%20Approach%20to%20small-scale%20Model%20Qualification%20(SSMQ)%20in%20Upstream%20(USP)%20Adeno-Associated%20Virus%20(AAV)%20Production-1.pngMultivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1Multivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-12026-06-01https://viralgen.com/personal-data-protection2025-07-31https://viralgen.com/resources/benefits-of-high-throughput-sequencing-based-methods-for-in-depth-characterization-of-recombinant-aav-productshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-07-23https://viralgen.com/resources/enhancing-the-upstream-performance-of-adeno-associated-virus-aav-vector-manufacturing-via-multivariate-data-analysishttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-07-23https://viralgen.com/resources/boosting-aav-manufacturing-performance-with-multivariate-data-analysishttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-01-17https://viralgen.com/newshttps://viralgen.com/hubfs/ESGCT%20AskBio%20PR%20Featured%20Image.pngESGCT AskBio PR Featured ImageESGCT AskBio PR Featured Imagehttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%20Apertura%20Press%20Release_1200x627_v1.1.gifVRLG Apertura Press Release_1200x627_v1.1VRLG Apertura Press Release_1200x627_v1.1https://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v12025-01-24https://viralgen.com/ai-policy2026-03-17https://viralgen.com/resources/addressing-manufacturing-and-characterization-challenges-and-opportunities-with-novel-aav-capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Multivariate%20Approach%20to%20small-scale%20Model%20Qualification%20(SSMQ)%20in%20Upstream%20(USP)%20Adeno-Associated%20Virus%20(AAV)%20Production-1.pngMultivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-1Multivariate Approach to small-scale Model Qualification (SSMQ) in Upstream (USP) Adeno-Associated Virus (AAV) Production-12026-06-08https://viralgen.com/resources/optimizing-scale-up-to-2000l-in-upstream-processing2025-03-14https://viralgen.com/resources/improving-scalability-and-productivity-of-transient-transfection-aav-production2025-03-14https://viralgen.com/resources/integrating-raman-spectroscopy-and-genome-scale-modeling-to-enhance-aav-upstream-manufacturinghttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-07-23https://viralgen.com/resources/pioneering-raav-characterization-with-hts-technologieshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-01-17https://viralgen.com/process2026-05-19https://viralgen.com/insights/viralgen-receives-cgmp-certification-to-produce-raav-commercial-grade-product-at-new-facility-in-san-sebastian-spainhttps://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Image2024-09-26https://viralgen.com/expert-insightshttps://viralgen.com/hubfs/Life%20Science%20Connect%20Webinar.mp4/medium.jpgLife Science Connect WebinarLife Science Connect Webinarhttps://viralgen.com/hubfs/Life%20Science%20Connect%20Webinar.mp42062nonohttps://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4/medium.jpgLife Science In Action VIRALGEN 11_12 v3Life Science In Action VIRALGEN 11_12 v3https://viralgen.com/hubfs/Life%20Science%20In%20Action%20VIRALGEN%2011_12%20v3.mp4120nonohttps://viralgen.com/hubfs/10760_20251020115848541_gen_17thoct_1400et_od.mp4/medium.jpg10760_20251020115848541_gen_17thoct_1400et_od10760_20251020115848541_gen_17thoct_1400et_odhttps://viralgen.com/hubfs/10760_20251020115848541_gen_17thoct_1400et_od.mp43256nonohttps://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen%20@%20OPCU%20-%20July%2017th%202025.mp4/medium.jpgViralgen Outsourced Pharma Capacity Update July 2025 - Fill/FinishDon't miss Viralgen's presentation at Outsourced Pharma's Cell & Gene Therapy Capacity Update, where CCO Andy Holt unveiled an exciting initiative that will accelerate data acquisition for investor funding. Watch now us to discover how Viralgen drives industry progress through innovation and strategic support.https://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen%20@%20OPCU%20-%20July%2017th%202025.mp41235nonohttps://viralgen.com/hubfs/Andy%20Holt%20@%20MOTM%202025.mp4/medium.jpgAndy Holt @ MOTM 2025Andy Holt @ MOTM 2025https://viralgen.com/hubfs/Andy%20Holt%20@%20MOTM%202025.mp4849nonohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nono2026-05-19https://viralgen.com/news/viralgen-and-ctnnb1-foundation-partner-to-manufacture-a-new-gene-therapy-for-ctnnb1-syndromehttps://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V1https://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease2025-07-31https://viralgen.com/resources/development-of-an-analytical-method-for-aav-capsid-protein-for-use-in-stability-studies2024-11-18https://viralgen.com/resources/webinar-making-a-meaningful-impact-in-aavhttps://viralgen.com/hubfs/Andy%20Holt%20@%20MOTM%202025.mp4/medium.jpgAndy Holt @ MOTM 2025Andy Holt @ MOTM 2025https://viralgen.com/hubfs/Andy%20Holt%20@%20MOTM%202025.mp4849nonohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG_MotM%202025%20Webinar_1200x627_v1.gifVRLG_MotM 2025 Webinar_1200x627_v1VRLG_MotM 2025 Webinar_1200x627_v1https://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnail2025-11-03https://viralgen.com/manufacturing-platformshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Manufacturing-platforms_chart_V2.svgManufacturing-platforms_chart_V2Manufacturing-platforms_chart_V2https://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAhttps://viralgen.com/hubfs/Triple-Plasmid%20Transfection.pngTriple-Plasmid TransfectionTriple-Plasmid Transfection2025-10-07https://viralgen.com/resources/technology-transfer-process-excellence-with-an-aav-comparability-study2025-03-14https://viralgen.com/resources/addressing-barriers-in-gene-therapy2025-03-14https://viralgen.com/news/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regeneratehttps://viralgen.com/hubfs/VRLG%20Apertura%20Press%20Release_1200x627_v1.1.gifVRLG Apertura Press Release_1200x627_v1.1VRLG Apertura Press Release_1200x627_v1.1https://viralgen.com/hubfs/VRLG%202026%20AskBio%20ASGCT%20Press%20Release_1200x627_v1.gifVRLG 2026 AskBio ASGCT Press Release_1200x627_v1VRLG 2026 AskBio ASGCT Press Release_1200x627_v1https://viralgen.com/hubfs/AskBios%20Viralgen%20to%20Supply%20Commercial-Scale%20Drug%20Product%20for%20REGENERATE-PD%20Investigational%20Gene%20Therapy%20Phase%20II%20Trial%20for%20Parkinson%E2%80%99s%20Disease.gifAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s DiseaseAskBios Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Diseasehttps://viralgen.com/hubfs/VRLG%20Elaaj%20Bio%20Press%20Release%202026_V1.gifVRLG Elaaj Bio Press Release 2026_V1VRLG Elaaj Bio Press Release 2026_V12026-04-20https://viralgen.com/resources/adding-consistency-to-gene-therapy-manufacturing2024-10-16https://viralgen.comhttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Jimmy%20Vanhove_Q1_V1.2.mp4/medium.jpgViralgen_Voices from the Field_Jimmy Vanhove_Q1_V1.2Viralgen_Voices from the Field_Jimmy Vanhove_Q1_V1.2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Jimmy%20Vanhove_Q1_V1.2.mp443nonohttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Jimmy%20Vanhove_Q2_V1.2.mp4/medium.jpgViralgen_Voices from the Field_Jimmy Vanhove_Q2_V1.2Viralgen_Voices from the Field_Jimmy Vanhove_Q2_V1.2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Jimmy%20Vanhove_Q2_V1.2.mp449nonohttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Maria%20Orio-2_V1.2.mp4/medium.jpgViralgen_Voices from the Field_Maria Orio-2_V1.2Viralgen_Voices from the Field_Maria Orio-2_V1.2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Maria%20Orio-2_V1.2.mp457nonohttps://viralgen.com/hubfs/Viralgen%20Aava%20home%20page%20section_V1.mp4/medium.jpgViralgen Aava home page section_V1Viralgen Aava home page section_V1https://viralgen.com/hubfs/Viralgen%20Aava%20home%20page%20section_V1.mp41nonohttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_C%C3%A9sar%20Trigueros_Q2_V2.mp4/medium.jpgViralgen_Voices from the Field_César Trigueros_Q2_V2Viralgen_Voices from the Field_César Trigueros_Q2_V2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_C%C3%A9sar%20Trigueros_Q2_V2.mp443nonohttps://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen-Video-Clip-optimized.mp4/medium.jpgWell-equipped to advance your gene therapyServing as the world’s manufacturing center of excellence for AAV demands all the right resources be right at hand. And at Viralgen, they are. That uniquely positions us to help our clients find a more direct path to commercialization based on our proven science, new-fashioned thinking, focused capacity, and a true-to-target track record.https://viralgen.com/hubfs/Brand%20Assets/Videos/Viralgen-Video-Clip-optimized.mp413nonohttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Viralgen%20Aava%20home%20page%20section_V1.webm/medium.jpgViralgen Aava home page section_V1Viralgen Aava home page section_V1https://viralgen.com/hubfs/Viralgen%20Aava%20home%20page%20section_V1.webm1nonohttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_C%C3%A9sar%20Trigueros_Q1_V1.2.mp4/medium.jpgViralgen_Voices from the Field_César Trigueros_Q1_V1.2Viralgen_Voices from the Field_César Trigueros_Q1_V1.2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_C%C3%A9sar%20Trigueros_Q1_V1.2.mp433nonohttps://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Ana%20Barbas_V2.mp4/medium.jpgViralgen_Voices from the Field_Ana Barbas_V2Viralgen_Voices from the Field_Ana Barbas_V2https://viralgen.com/hubfs/Viralgen_Voices%20from%20the%20Field_Ana%20Barbas_V2.mp475nonohttps://viralgen.com/hubfs/Home-GEN26-aav-success-section-shape.pngHome-GEN26-aav-success-section-shapeHome-GEN26-aav-success-section-shapehttps://viralgen.com/hubfs/Anna.jpgAnnaAnnahttps://viralgen.com/hubfs/Home-gen26-section-shape-1.pngHome-gen26-section-shape-1Home-gen26-section-shape-1https://viralgen.com/hubfs/Maria_1.jpgMaria_1Maria_1https://viralgen.com/hubfs/Rectangle%2037.pngRectangle 37Rectangle 37https://viralgen.com/hubfs/Home-gen26-gem-mask-1.pngHome-gen26-gem-mask-1Home-gen26-gem-mask-1https://viralgen.com/hubfs/Home-gem-gen26.pngHome-gem-gen26Home-gem-gen26https://viralgen.com/hubfs/Jimmy_2.jpgJimmy_2Jimmy_2https://viralgen.com/hubfs/Viralgen%202026%20Homepage%20FI.pngViralgen 2026 Homepage FIViralgen 2026 Homepage FIhttps://viralgen.com/hubfs/Viralgen_building-gem2-2-2.pngViralgen_building-gem2-2-2Viralgen_building-gem2-2-2https://viralgen.com/hubfs/Cesar_1.jpgCesar_1Cesar_1https://viralgen.com/hubfs/lab-Icon-square.svglab-Icon-squarelab-Icon-squarehttps://viralgen.com/hubfs/home_gem_3-2.pnghome_gem_3-2home_gem_3-2https://viralgen.com/hubfs/Team-icon-square.svgTeam-icon-squareTeam-icon-squarehttps://viralgen.com/hubfs/Cesar_2.jpgCesar_2Cesar_2https://viralgen.com/hubfs/Jimmy_1.jpgJimmy_1Jimmy_12026-06-22https://viralgen.com/resources/optimizing-scale-up-of-aav-gene-therapy-in-upstream-processing2024-10-16https://viralgen.com/resources/unlocking-efficiency-in-aav-manufacturing-with-doe-insightshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2025-01-17https://viralgen.com/contact2026-05-19https://viralgen.com/late-phase-productionhttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp4/medium.jpgWebinar: Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV CapsidsLSC Connect Webinar June 2, 2026 Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsidshttps://viralgen.com/hubfs/LSC%20Connect%20Webinar%20June%202%2c%202026%20Webinar%20Addressing%20Manufacturing%20and%20Characterization%20Challenges%20and%20Opportunities%20with%20Novel%20AAV%20Capsids.mp43790nonohttps://viralgen.com/hubfs/Repeatability%20and%20Intermediate%20Precision%20of%20a%20Genome%20Integrity%20Assay%20for%20rAAV%20by%20Long-Read%20Sequencing.pngRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read SequencingRepeatability and Intermediate Precision of a Genome Integrity Assay for rAAV by Long-Read Sequencinghttps://viralgen.com/hubfs/VRLG%20LSC%20Webinar%20Thumbnail.pngVRLG LSC Webinar ThumbnailVRLG LSC Webinar Thumbnailhttps://viralgen.com/hubfs/ddPCR-Based%20Quantification%20and%20Fragment%20Analysis%20of%20Residual%20E1A%20in%20rAAV%20Products_%20Method%20Validation%20and%20Correlation%20with%20Total%20Host%20Cell%20DNA.pngddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNAddPCR-Based Quantification and Fragment Analysis of Residual E1A in rAAV Products_ Method Validation and Correlation with Total Host Cell DNA2026-05-19https://viralgen.com/insights/rare-disease-day-2023https://viralgen.com/hubfs/VRLG%20RDD%202026%20Blog%20Featured%20Image.pngVRLG RDD 2026 Blog Featured ImageVRLG RDD 2026 Blog Featured Image2024-09-27